China Resources Pharmaceutical Group Completes RMB1.1 Billion Corporate Bond Issuance

Reuters

2025/11/18

China Resources Pharmaceutical Group Completes RMB1.1 Billion Corporate Bond Issuance

China Resources Pharmaceutical Group Ltd. has announced the completion of the public issuance of the second tranche of its 2025 Corporate Bonds in the People's Republic of China (PRC). The second tranche was issued by CR Pharmaceutical Holdings, a wholly-owned subsidiary of the company, in an aggregate principal amount of RMB 1.1 billion. This tranche carries a term of three years and a coupon rate of 1.78% per annum. The net proceeds from this issuance will be used for production expenditures, including repayment of corporate debts, replenishment of working capital, project development and operation expenditures, investments related to scientific and technological innovations, and other lawful purposes. This announcement follows an earlier issuance of the first tranche, as referenced in the company's prior announcement dated 21 October 2025. No URL for the full prospectus is included in the document.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2584318519"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584318519\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584318519?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584318519","market":"fut","top_or_hot":-1,"title":"China Resources Pharmaceutical Group Completes RMB1.1 Billion Corporate Bond Issuance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      China Resources Pharmaceutical Group Completes RMB1.1 Billion Corporate Bond Issuance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        China Resources Pharmaceutical Group Ltd. has announced the completion of the public issuance of the second tranche of its 2025 Corporate Bonds in the People's Republic of China (PRC). The second tranche was issued by CR Pharmaceutical Holdings, a wholly-owned subsidiary of the company, in an aggregate principal amount of RMB 1.1 billion. This tranche carries a term of three years and a coupon rate of 1.78% per annum. The net proceeds from this issuance will be used for production expenditures, including repayment of corporate debts, replenishment of working capital, project development and operation expenditures, investments related to scientific and technological innovations, and other lawful purposes. This announcement follows an earlier issuance of the first tranche, as referenced in the company's prior announcement dated 21 October 2025. No URL for the full prospectus is included in the document.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Resources Pharmaceutical Group Completes RMB1.1 Billion Corporate Bond Issuance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Resources Pharmaceutical Group Completes RMB1.1 Billion Corporate Bond Issuance\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-18 19:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      China Resources Pharmaceutical Group Completes RMB1.1 Billion Corporate Bond Issuance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        China Resources Pharmaceutical Group Ltd. has announced the completion of the public issuance of the second tranche of its 2025 Corporate Bonds in the People's Republic of China (PRC). The second tranche was issued by CR Pharmaceutical Holdings, a wholly-owned subsidiary of the company, in an aggregate principal amount of RMB 1.1 billion. This tranche carries a term of three years and a coupon rate of 1.78% per annum. The net proceeds from this issuance will be used for production expenditures, including repayment of corporate debts, replenishment of working capital, project development and operation expenditures, investments related to scientific and technological innovations, and other lawful purposes. This announcement follows an earlier issuance of the first tranche, as referenced in the company's prior announcement dated 21 October 2025. No URL for the full prospectus is included in the document.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1570","symbol_name":"華潤系","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL4wr5mS:1","article_id":"2584318519","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584318519","pubTimestamp":1763465166,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"China Resources Pharmaceutical Group Ltd. has announced the completion of the public issuance of the second tranche of its 2025 Corporate Bonds in the People's Republic of China . The second tranche was issued by CR Pharmaceutical Holdings, a wholly-owned subsidiary of the company, in an aggregate principal amount of RMB 1.1 billion. This tranche carries a term of three years and a coupon rate of 1.78% per annum. The net proceeds from this issuance will be used for production expenditures, including repayment of corporate debts, replenishment of working capital, project development and operation expenditures, investments related to scientific and technological innovations, and other lawful purposes. This announcement follows an earlier issuance of the first tranche, as referenced in the company's prior announcement dated 21 October 2025. No URL for the full prospectus is included in the document.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1570":"华润系","03320":"华润医药","BK1191":"制药"},"translate_title":"华润医药集团完成人民币11亿元公司债券发行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":0.9},"content_text":"China Resources Pharmaceutical Group Completes RMB1.1 Billion Corporate Bond Issuance\n    \n\n        China Resources Pharmaceutical Group Ltd. has announced the completion of the public issuance of the second tranche of its 2025 Corporate Bonds in the People's Republic of China (PRC). The second tranche was issued by CR Pharmaceutical Holdings, a wholly-owned subsidiary of the company, in an aggregate principal amount of RMB 1.1 billion. This tranche carries a term of three years and a coupon rate of 1.78% per annum. The net proceeds from this issuance will be used for production expenditures, including repayment of corporate debts, replenishment of working capital, project development and operation expenditures, investments related to scientific and technological innovations, and other lawful purposes. This announcement follows an earlier issuance of the first tranche, as referenced in the company's prior announcement dated 21 October 2025. No URL for the full prospectus is included in the document.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}